APG Asset Management N.V. Acquires 134,280 Shares of Hologic, Inc. (NASDAQ:HOLX)

APG Asset Management N.V. grew its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 230.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 192,506 shares of the medical equipment provider's stock after acquiring an additional 134,280 shares during the period. APG Asset Management N.V. owned about 0.09% of Hologic worth $13,402,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in HOLX. Norges Bank purchased a new stake in shares of Hologic in the fourth quarter valued at approximately $133,414,000. Boston Partners boosted its position in shares of Hologic by 81.0% during the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock worth $257,959,000 after acquiring an additional 1,602,463 shares in the last quarter. Invesco Ltd. boosted its stake in Hologic by 16.4% in the fourth quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock valued at $293,434,000 after acquiring an additional 572,187 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of Hologic by 32.7% during the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider's stock worth $159,911,000 after buying an additional 544,889 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Hologic in the fourth quarter valued at about $27,007,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Argus cut Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Leerink Partners cut shares of Hologic from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. William Blair reiterated an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Citigroup lowered their target price on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Finally, Needham & Company LLC cut shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 target price for the company. in a research report on Monday, February 3rd. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $84.62.

Hologic Price Performance

NASDAQ HOLX traded down $1.36 during mid-day trading on Wednesday, hitting $56.50. The stock had a trading volume of 1,011,699 shares, compared to its average volume of 1,919,952. Hologic, Inc. has a twelve month low of $56.27 and a twelve month high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The stock has a market capitalization of $12.68 billion, a price-to-earnings ratio of 17.82, a PEG ratio of 2.14 and a beta of 0.82. The firm's 50 day moving average is $62.04 and its 200 day moving average is $71.25.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.